NEW YORK--(BUSINESS WIRE)--Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system related edema, today announced that the Company issued a second-quarter 2016 report.
Highlights include newly analyzed data from 12-month follow-ups of patients in its Phase 2 randomized, double blind trial of CIRARA™ in large hemispheric infarctions.
